查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1985626

癌症疼痛管理市場：2026-2032年全球市場預測（按藥物類別、給藥途徑、分銷管道、最終用戶和應用分類）

Cancer Pain Management Market by Drug Class, Route Of Administration, Distribution Channel, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，癌症疼痛管理市場價值將達到 83.5 億美元，到 2026 年將成長至 88.7 億美元，到 2032 年將達到 129.1 億美元，複合年成長率為 6.41%。

主要市場統計數據
基準年 2025 83.5億美元
預計年份：2026年 88.7億美元
預測年份 2032 129.1億美元
複合年成長率 (%) 6.41%

這是一本權威的癌症疼痛管理入門指南，系統地說明了臨床複雜性、多學科護理以及整個醫療保健系統相關人員的戰略重點。

癌症疼痛管理在腫瘤學、安寧療護和醫療保健系統經濟學的交會點佔據著至關重要的地位。腫瘤學的進步延長了許多患者的生存期，凸顯了對細緻入微且持續的疼痛管理方法的需求日益成長，以維持患者的功能和生活品質。如今，臨床醫生必須平衡急性手術相關疼痛、慢性癌症相關疼痛症候群、複雜的神經病變疼痛、合併症、多重用藥以及患者的多樣化需求。因此，疼痛管理策略必須具有適應性、以實證醫學為基礎，並與不斷發展的護理標準保持一致。

臨床個體化、鴉片類藥物的合理使用、新的給藥技術以及支付方主導的結果如何重塑癌症疼痛管理在各種護理路徑中的應用？

目前，癌症疼痛管理正經歷多項變革，這些變革正在改變臨床實踐和商業策略的整體方向。首先，隨著疼痛亞型表現型分析的改進以及對神經病變性疼痛和傷害性疼痛機制理解的加深，鎮痛治療方案正明顯地向個體化方向發展。這種轉變促使臨床醫師根據疼痛病因和患者的特定風險因子來選擇治療方法，而不是依賴統一的治療方案。

評估 2025 年美國關稅措施對癌症止痛藥物的供應和取得的多方面營運和採購影響。

2025年實施的政策和貿易措施帶來了新的趨勢，影響癌症止痛藥物的採購、定價行為和供應鏈規劃。影響進口活性藥物成分和成品製劑的關稅調整，增加了製造商和醫療保健系統採購決策的複雜性。許多相關人員正在透過重新評估其供應商組合，並加快生產和原料採購多元化策略來應對關稅帶來的成本壓力。

透過詳細的細分分析，明確產品定位、與臨床路徑的一致性以及按藥物類別、給藥途徑、分銷管道、使用者和應用進行分銷差異化。

基於細分市場的分析揭示了不同藥物類別、給藥途徑、分銷管道、終端用戶環境和特定應用需求的臨床和商業性趨勢差異。藥物類別包括輔助鎮痛藥、局部麻醉劑、非類固醇消炎劑和鴉片類藥物。在輔助性止痛藥中，抗驚厥藥、抗憂鬱症和皮質類固醇等特定亞類藥物針對癌症疼痛的神經性和發炎性成分；而鴉片類藥物則進一步分為天然、半合成和合成藥物，它們具有不同的受體譜、安全性考慮因素和監管規定。

對美洲、歐洲、中東和非洲以及亞太地區的准入模式、處方實踐和供應鏈影響進行區域分析。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的醫療服務取得模式、治療方法選擇和相關人員的優先事項均有顯著影響。在美洲，綜合醫療服務體系和專科藥局的強大影響力正推動新型給藥平台和病患支援計畫的快速普及。同時，監管機構對鴉片類藥物安全性的重視持續影響處方規範和合理用藥工作。相較之下，歐洲、中東和非洲地區的支付方結構和採購體系則呈現出多元化的特點，部分市場存在集中式競標系統，而當地藥品目錄根深蒂固，且各地區的姑息治療基礎設施也存在差異。

主要企業如何透過研發、管理方法創新、經銷夥伴以及真實世界數據來滿足癌症疼痛治療中尚未滿足的需求，從而實現差異化？

隨著各公司尋求差異化策略以應對癌症疼痛管理中複雜的臨床問題和支付方的需求，競爭格局正在改變。主要企業正將針對非鴉片類藥物和輔助性治療的標靶研究與新型給藥系統的投資相結合，以最佳化安全性和提高用藥依從性。同時，學名藥和專科藥物生產商也在拓展支持用藥依從性的服務，例如病患教育和護理師主導的劑量調整方案，同時強調供應可靠性和成本效益。

為領導者提供可操作且優先考慮的建議，以加強供應韌性，推廣遏制鴉片類藥物使用的治療方法，並使商業模式與可衡量的臨床結果保持一致。

產業領導者可以透過實施以下幾項切實可行的建議，採取果斷行動，從而獲得臨床認可和商業性優勢。首先，應優先考慮供應鏈多元化和緊急生產夥伴關係，以確保產品供應穩定，同時降低貿易和原料中斷帶來的風險。其次，應加速開發和推廣非鴉片類療法及輔助藥物，以應對癌症疼痛的神經病變和發炎性因素，從而支持旨在減少鴉片類藥物使用的臨床方案。

嚴謹的混合方法研究框架，結合專家訪談、文獻整合和真實世界資料（REW），同時確保在限制和倫理保障方面保持透明。

本分析整合了混合方法研究的成果，該方法結合了定性和定量方法，以確保可靠的檢驗。主要研究包括對臨床醫生、藥房經理、醫院採購負責人和保險公司代表進行結構化訪談，以了解他們對臨床需求、處方集決策標準和採購趨勢的第一手觀點。此外，還對同行評審的臨床指南、監管公告和政策分析進行了文獻綜述，以補充這些研究結果，從而將不斷發展的標準和合理使用要求置於更廣闊的背景下進行分析。

策略結論強調在臨床、商業和政策領域開展合作，將創新轉化為可靠的、以患者為中心的癌症疼痛治療。

總之，癌症疼痛管理正處於策略轉折點，臨床創新、政策壓力和供應鏈現實在此交匯，重新定義了止痛藥的給藥和評估方式。個人化治療方案、非鴉片類藥物療法和給藥技術的進步為改善病患功能和安全性提供了重要契機，但只有當相關人員就藥物管理、實證實踐和取得模式達成共識時，這些成果才能得以實現。不斷變化的價格和採購環境進一步凸顯了建立具有韌性的供應策略和合約機制以保障醫療服務連續性的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：癌症疼痛管理市場：依藥物類別分類

  • 輔助止痛藥
    • 抗驚厥藥物
    • 抗憂鬱症
    • 皮質類固醇
  • 局部麻醉劑
  • NSAIDs
  • 鴉片類藥物
    • 自然的
    • 半合成
    • 合成

第9章：癌症疼痛管理市場：依給藥途徑分類

  • 口服
    • 膠囊
    • 解決方案
    • 藥片
  • 腸外
    • 肌肉內部
    • 靜脈
    • 皮下
  • 舌下
    • 電影
    • 錠劑
  • 經皮

第10章：癌症疼痛管理市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章：癌症疼痛管理市場：以最終用戶分類

  • 癌症專科醫療機構
  • 居家照護
  • 醫院

第12章 癌症疼痛管理市場：依應用領域分類

  • 骨轉移引起的疼痛
  • 神經性疼痛
  • 內臟疼痛

第13章 癌症疼痛管理市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 癌症疼痛管理市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 癌症疼痛管理市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國癌症疼痛管理市場

第17章：中國癌症疼痛管理市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Aegis Therapeutics, LLC
  • Aptinyx Inc.
  • Astellas Pharma Inc.
  • Bausch Health Companies Inc.
  • Baxter International Inc.
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Glaxosmithkline PLC
  • Grunenthal Group
  • Johnson & Johnson Services, Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi SA
  • Scilex Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Trevena Inc.
Product Code: MRR-144C638C8F7B

The Cancer Pain Management Market was valued at USD 8.35 billion in 2025 and is projected to grow to USD 8.87 billion in 2026, with a CAGR of 6.41%, reaching USD 12.91 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.35 billion
Estimated Year [2026] USD 8.87 billion
Forecast Year [2032] USD 12.91 billion
CAGR (%) 6.41%

An authoritative introduction to cancer pain management that frames clinical complexity, multidisciplinary care, and strategic priorities for stakeholders across health systems

Cancer pain management occupies a pivotal intersection between oncology care, palliative medicine, and health system economics. Advances in oncology have extended survival for many patients, which in turn has broadened the need for nuanced, sustained approaches to pain control that preserve function and quality of life. Clinicians now balance acute procedural pain, chronic cancer-related pain syndromes, and complex neuropathic presentations alongside comorbidities, polypharmacy, and diverse patient preferences. Consequently, pain management strategies must be adaptable, evidence-driven, and aligned with evolving standards of care.

Across care settings, the imperative is to deliver targeted analgesia while minimizing adverse effects and dependence risks. This requires integration of pharmacologic options spanning adjuvant analgesics, local anesthetics, nonsteroidal anti-inflammatory drugs, and opioid therapies with nonpharmacologic modalities and interventional techniques. Regulatory frameworks, public health priorities on opioid stewardship, and payer policies are reshaping provider decision-making. Moreover, patient-centered models that incorporate shared decision-making and outcomes measurement are becoming central to defining value in therapy selection.

Given these complexities, stakeholders need consolidated, clinically rigorous guidance that synthesizes therapeutic modalities, route-of-administration considerations, distribution dynamics, and end-user requirements. This executive summary distills strategic insights and practical recommendations designed to inform clinical leaders, product strategists, and health systems as they adapt to a rapidly changing therapeutic landscape for cancer-associated pain.

How clinical personalization, opioid stewardship, new delivery technologies, and payer-driven outcomes are reshaping cancer pain management across care pathways

The landscape of cancer pain management is undergoing several transformative shifts that collectively reorient clinical practice and commercial strategy. First, there is a measurable move toward personalized analgesic regimens driven by improved phenotyping of pain subtypes and a clearer understanding of neuropathic versus nociceptive mechanisms. This shift is encouraging clinicians to select therapies based on pain etiology and patient-specific risk factors rather than a one-size-fits-all algorithm.

Simultaneously, opioid stewardship initiatives and heightened scrutiny of opioid prescribing are accelerating adoption of multimodal approaches that emphasize adjuvant analgesics, regional techniques, and targeted non-opioid pharmacotherapies. These changes are compounded by the emergence of novel delivery platforms and transdermal systems that improve adherence and minimize systemic exposure. Digital therapeutics, remote monitoring, and telemedicine are further altering care pathways by enabling continuous assessment of pain, side effects, and patient-reported outcomes, which supports more responsive titration of therapy.

On the commercial front, supply chain resilience and strategic partnerships between specialty pharmacies, hospital procurement teams, and manufacturers are reshaping distribution. Payers are increasingly focused on outcomes and cost-containment, prompting new contracting models that reward improved functional outcomes and reduced hospitalization. Taken together, these shifts call for adaptive clinical protocols, investment in data-driven monitoring, and collaborative policy engagement to ensure patients receive effective, safe, and accessible pain care.

Assessing the multifaceted operational and procurement consequences of 2025 United States tariff measures on availability and access to cancer pain therapeutics

Policy and trade measures enacted in 2025 have introduced new dynamics that influence procurement, pricing behavior, and supply chain planning for cancer pain therapeutics. Tariff adjustments affecting imported active pharmaceutical ingredients and finished dosage forms have increased the complexity of sourcing decisions for manufacturers and health systems. Many stakeholders have responded by reassessing supplier portfolios and accelerating strategies to diversify manufacturing and raw-material sourcing to mitigate exposure to tariff-driven cost pressures.

For hospital systems and pharmacy networks that manage formularies and procurement, the cumulative effect has been a sharper focus on total cost of care. Procurement teams are negotiating longer-term supply agreements, seeking contractual protections against price volatility, and prioritizing suppliers with vertically integrated capabilities. In parallel, some manufacturers have evaluated onshore or nearshore manufacturing options and strategic partnerships to preserve market access and reduce vulnerability to future trade uncertainties.

These developments also elevate the importance of transparent pricing arrangements and value-based contracting that align payment with measurable clinical outcomes. Clinicians and pharmacy leaders are adapting by emphasizing clinical pathways that demonstrate cost-effectiveness, promoting therapeutic alternatives where clinically appropriate, and engaging with payers to ensure continuity of access for patients with the most significant needs. Ultimately, ongoing policy monitoring and proactive supply chain strategies will be essential to sustaining reliable access to cancer pain medications in a more tariff-sensitive environment.

Detailed segmentation insights that illuminate product positioning, clinical pathway alignment, and distribution differentiation across drug classes, routes, channels, users, and applications

A segmentation-driven analysis reveals differentiated clinical and commercial dynamics across drug classes, routes of administration, distribution channels, end-user settings, and application-specific needs. Based on drug class, the landscape encompasses adjuvant analgesics, local anesthetics, nonsteroidal anti-inflammatory drugs, and opioids. Within adjuvant analgesics, specific subgroups such as anticonvulsants, antidepressants, and corticosteroids address neuropathic and inflammatory components of cancer pain, while opioids are further categorized into natural, semi-synthetic, and synthetic agents that vary in receptor profiles, safety considerations, and regulatory oversight.

Route of administration is another critical axis of differentiation, with oral, parenteral, sublingual, and transdermal options shaping real-world use. Oral therapies are commonly delivered as capsules, solutions, or tablets and remain central to chronic outpatient management, whereas parenteral formulations-delivered intramuscularly, intravenously, or subcutaneously-are essential for acute, procedural, or inpatient care. Sublingual modalities, including films and lozenges, provide rapid onset and convenience for breakthrough pain, and transdermal systems support sustained delivery with adherence advantages in select populations.

Distribution channel nuances inform access and patient experience through hospital pharmacy, online pharmacy, and retail pharmacy pathways, each of which has distinct procurement, dispensing, and stewardship workflows. End-user segmentation spans cancer institutes, home care environments, and hospitals, which differ in clinical expertise, monitoring capabilities, and resource intensity. Finally, application-specific considerations-such as bone metastasis pain, neuropathic pain, and visceral pain-require tailored analgesic strategies and care pathways. Together, these segmentation lenses guide product positioning, clinical guideline development, and targeted stakeholder engagement to meet varied clinical needs and operational realities.

A regional analysis of access models, prescribing practices, and supply chain implications across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics exert powerful influence on access models, therapeutic preferences, and stakeholder priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, integrated delivery systems and a strong specialty pharmacy footprint emphasize rapid adoption of novel delivery platforms and patient support programs, while regulatory focus on opioid safety continues to shape prescribing norms and stewardship initiatives. Contrastively, Europe, Middle East & Africa present a mosaic of payer structures and procurement arrangements, where centralized tendering in some markets coexists with highly localized formularies and differing palliative care infrastructures.

Asia-Pacific markets show marked heterogeneity in infrastructure maturity, with some urban centers adopting advanced multimodal pain management pathways and telemedicine-enabled follow-up, while other areas contend with fragmented access and supply chain constraints. Across all regions, demographic trends and rising survivorship are increasing demand for sustained, patient-centered pain management solutions, but the pathways to access differ based on reimbursement models, local regulatory priorities, and the prevalence of community-based versus hospital-centric care.

Transitioning from regional characteristics to operational implications, stakeholders must tailor clinical education, distribution partnerships, and evidence generation strategies to regional payer expectations and regulatory frameworks. By aligning product dossiers and value narratives with region-specific care models and procurement mechanisms, manufacturers and health systems can better support clinicians and patients within each distinct regional context.

How leading companies are differentiating through R&D, delivery innovation, distribution partnerships, and real-world evidence to address the unmet needs in cancer pain care

Competitive dynamics are evolving as companies pursue differentiated strategies to address clinical complexity and payer demands in cancer pain management. Leading innovators are combining targeted research into non-opioid and adjuvant therapies with investments in novel delivery systems that optimize safety and adherence. In parallel, generic and specialty manufacturers are emphasizing supply reliability and cost-efficiency while expanding services that support adherence, such as patient education and nurse-led titration programs.

Partnerships between pharmaceutical companies and specialty pharmacies or home infusion providers are becoming increasingly important to streamline distribution and support complex dosing regimens. Strategic alliances with technology firms are enabling remote monitoring solutions that feed real-world evidence into value dossiers, strengthening payer negotiations and post-market surveillance. Meanwhile, companies focused on interventional pain technologies and regional anesthetic agents are aligning with clinical centers of excellence to build evidence for procedural pain management protocols.

Across these approaches, successful market participants balance clinical credibility with operational excellence, investing in robust pharmacovigilance, supply chain transparency, and clinician engagement programs. By demonstrating measurable improvements in patient function, adherence, and reduced acute care utilization, companies can strengthen their value proposition to providers and payers while addressing unmet needs in cancer-associated pain management.

Practical and prioritized recommendations for leaders to strengthen supply resilience, advance opioid-sparing therapies, and align commercial models with measurable clinical outcomes

Industry leaders can act decisively to capture clinical trust and commercial advantage by operationalizing several pragmatic recommendations. First, prioritize diversification of supply chains and contingency manufacturing partnerships to reduce exposure to trade and raw-material disruptions while maintaining consistent product availability. At the same time, accelerate development and adoption of non-opioid therapeutics and adjuvant agents that address neuropathic and inflammatory components of cancer pain, thereby supporting opioid-sparing clinical algorithms.

Second, embed digital monitoring and patient-reported outcome tools into care pathways to enable responsive titration, detect adverse events earlier, and generate real-world data that supports value-based contracting. Concurrently, cultivate payer relationships around outcomes measurement by proposing pilot agreements that align reimbursement with functional gains and reductions in acute care utilization. Third, invest in clinician education and stewardship programs that provide practical guidance for multimodal regimens, safe opioid prescribing, and interventional techniques where appropriate.

Finally, tailor commercialization and access plans to the nuances of distribution channels and end-user settings; for example, ensure hospital formularies, home care providers, and specialty pharmacies have the training and materials needed to support complex regimens. Operationalizing these recommendations will require cross-functional collaboration among clinical affairs, supply chain, reimbursement, and commercial teams to translate strategy into measurable improvements in patient care.

A rigorous mixed-methods research framework combining expert interviews, literature synthesis, and real-world evidence with transparency on limitations and ethical safeguards

This analysis synthesizes findings derived from a mixed-methods research approach combining qualitative and quantitative techniques to ensure robust triangulation. Primary research included structured interviews with clinicians, pharmacy leaders, hospital procurement officers, and payer representatives to capture frontline perspectives on clinical needs, formulary decision criteria, and procurement dynamics. These insights were complemented by secondary literature reviews of peer-reviewed clinical guidelines, regulatory announcements, and policy analyses to contextualize evolving standards and stewardship imperatives.

Real-world evidence sources, including anonymized claims and utilization patterns, informed assessments of treatment pathways and administration settings without providing market sizing. The methodology prioritized data quality through cross-validation across independent sources and iterative expert review. Where divergent viewpoints emerged, the analysis explicitly flagged areas of clinical debate and operational uncertainty to aid decision-makers in prioritizing further inquiry.

Limitations of the methodology include variability in regional data availability, evolving regulatory landscapes that may change practice patterns, and heterogeneity in institutional protocols. To mitigate these limitations, the research incorporated sensitivity checks and sought corroboration from multiple stakeholders. Ethical considerations, including patient privacy and responsible use of clinical data, guided the research protocols and stakeholder engagements throughout the study.

A strategic conclusion emphasizing collaboration across clinical, commercial, and policy domains to translate innovation into reliable, patient-centered cancer pain care

In summary, cancer pain management is at a strategic inflection point where clinical innovation, policy pressures, and supply chain realities intersect to redefine how analgesia is delivered and valued. Advances in personalized approaches, non-opioid therapies, and delivery technologies offer meaningful opportunities to improve patient function and safety, but these gains will only be realized if stakeholders align on stewardship, evidence generation, and access models. The evolving tariff and procurement environment further underscore the need for resilient supply strategies and contracting mechanisms that protect continuity of care.

For clinicians, the priority is to integrate multimodal, mechanism-based regimens while leveraging monitoring tools to individualize treatment. For manufacturers and distributors, success depends on demonstrating value through real-world outcomes, securing reliable supply pathways, and engaging payers with pragmatic propositions. For health systems and payers, investments in stewardship, education, and outcome measurement will be critical to achieving sustainable, high-quality pain management for patients with cancer.

Ultimately, a collaborative approach that links clinical excellence with operational rigor and policy engagement will be essential to advance care. Stakeholders who act deliberately-balancing innovation with pragmatic supply and reimbursement strategies-will be best positioned to improve patient outcomes and system-level performance in cancer-related pain management.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Pain Management Market, by Drug Class

  • 8.1. Adjuvant Analgesics
    • 8.1.1. Anticonvulsants
    • 8.1.2. Antidepressants
    • 8.1.3. Corticosteroids
  • 8.2. Local Anesthetics
  • 8.3. Nsaids
  • 8.4. Opioids
    • 8.4.1. Natural
    • 8.4.2. Semi-Synthetic
    • 8.4.3. Synthetic

9. Cancer Pain Management Market, by Route Of Administration

  • 9.1. Oral
    • 9.1.1. Capsules
    • 9.1.2. Solutions
    • 9.1.3. Tablets
  • 9.2. Parenteral
    • 9.2.1. Intramuscular
    • 9.2.2. Intravenous
    • 9.2.3. Subcutaneous
  • 9.3. Sublingual
    • 9.3.1. Films
    • 9.3.2. Lozenges
  • 9.4. Transdermal

10. Cancer Pain Management Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Cancer Pain Management Market, by End User

  • 11.1. Cancer Institutes
  • 11.2. Home Care
  • 11.3. Hospitals

12. Cancer Pain Management Market, by Application

  • 12.1. Bone Metastasis Pain
  • 12.2. Neuropathic Pain
  • 12.3. Visceral Pain

13. Cancer Pain Management Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cancer Pain Management Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cancer Pain Management Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cancer Pain Management Market

17. China Cancer Pain Management Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AbbVie Inc.
  • 18.7. Aegis Therapeutics, LLC
  • 18.8. Aptinyx Inc.
  • 18.9. Astellas Pharma Inc.
  • 18.10. Bausch Health Companies Inc.
  • 18.11. Baxter International Inc.
  • 18.12. Bayer AG
  • 18.13. Biogen Inc.
  • 18.14. Boehringer Ingelheim International GmbH
  • 18.15. Eisai Co., Ltd.
  • 18.16. Eli Lilly and Company
  • 18.17. Glaxosmithkline PLC
  • 18.18. Grunenthal Group
  • 18.19. Johnson & Johnson Services, Inc.
  • 18.20. Merck & Co. Inc.
  • 18.21. Novartis AG
  • 18.22. Pfizer Inc.
  • 18.23. Regeneron Pharmaceuticals Inc.
  • 18.24. Sanofi SA
  • 18.25. Scilex Pharmaceuticals
  • 18.26. Teva Pharmaceutical Industries Ltd.
  • 18.27. Trevena Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER PAIN MANAGEMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER PAIN MANAGEMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ANTICONVULSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ANTICONVULSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NATURAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NATURAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NATURAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SEMI-SYNTHETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SEMI-SYNTHETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SEMI-SYNTHETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SYNTHETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SYNTHETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY FILMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY FILMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY FILMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY LOZENGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY LOZENGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY LOZENGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CANCER INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CANCER INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CANCER INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY BONE METASTASIS PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY BONE METASTASIS PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY BONE METASTASIS PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY VISCERAL PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY VISCERAL PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY VISCERAL PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. GCC CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GCC CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 208. GCC CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 209. GCC CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 210. GCC CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. GCC CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 212. GCC CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 213. GCC CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 214. GCC CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. GCC CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GCC CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. G7 CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. G7 CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 241. G7 CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 242. G7 CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 243. G7 CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. G7 CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 245. G7 CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 246. G7 CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 247. G7 CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. G7 CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. G7 CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 250. NATO CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. NATO CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 252. NATO CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 253. NATO CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 254. NATO CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 255. NATO CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 256. NATO CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 257. NATO CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 258. NATO CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. NATO CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. NATO CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)